Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 797-808

  Cui, Lian Hua ^a   Yu, Zhuang ^a   Zhang, Ting Ting ^a   Shin, Min Ho ^d   Kim, Hee Nam ^c   Choi, Jin Su ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b Chonnam National University Medical School   (South Korea)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^d Chonnam National University Hwasun Hospital ^*

Author keywords

methionine synthase 2756 A G polymorphisms; methylenetetrahydrofolate reductase 677 C T polymorphisms; non small cell lung. cancer; platinum based chemotherapy; susceptibility; thymidylate synthase polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CHINA; CODOMINANCE; CONTROLLED STUDY; DOMINANT INHERITANCE; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; MTR GENE; MULTIPLE CYCLE TREATMENT; RECESSIVE INHERITANCE; TYMS GENE;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CHINA; CISPLATIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE;

EID: 79959384942     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.27     Document Type: Article

References (51)

1. Yang G, Fan LJ, Tan et al.: Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 282, 1247-1253 (1999). (Pubitemid 29468496)
2. Shi J, Liu M, Zhang Q, Lu M, Quan H: Male and female adult population health status in China: a cross-sectional national survey. BMC Public Health 8, 277 (2008).
3. Yang L, Parkin DM, Li LD, Chen YD, Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90, 2157-2166 (2004). (Pubitemid 38869723)
4. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis: Lung Cancer 31, 139-148 (2001). (Pubitemid 32107010)
5. Ulrich CM, Robien K, McLeod HL: Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer 3, 912-920 (2003). (Pubitemid 37500176)
6. Rozen R: Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb. Haemost. 78, 523-526 (1997). (Pubitemid 27289296)
7. Jacques PF, Bostom AG, Williams RR et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9 (1996). (Pubitemid 26006560)
8. Shintani Y, Ohta M, Hirabayashi H et al.: New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int. J. Cancer 104, 790-795 (2003). (Pubitemid 36418519)
9. L. Sharpand, Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am. J. Epidemiol. 159, 423-443 (2004). (Pubitemid 38280289)
10. Leclerc D, Campeau E, Goyette P et al.: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/ cobalamin disorders. Hum. Mol. Genet. 5, 1867-1874 (1996). (Pubitemid 26413628)
11. Hung RJ, Hashibe, McKay MJ et al.: Folate-related genes and the risk of tobacco-related cancers in Central Europe. Carcinogenesis 28, 1334-1340 (2007).
12. Shen M, Rothman N, Berndt SI et al.: Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer 49, 299-309 (2005). (Pubitemid 41139142)
13. Siemianowicz K, Gminski J, Garczorz W et al.: Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small-cell lung cancer. Oncol. Rep. 10, 1341-1344 (2003).
14. Zhang XM, Miao XP, Tan W et al.: Association between genetic polymorphisms in methylentetrahydrofolate reductase and risk of lung cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27, 700-703 (2005).
15. Suzuki T, Matsuo K, Hiraki A et al.: Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis 28, 1718-1725 (2007). (Pubitemid 47303945)
16. Liu CS, Tsai CW, T. Hsia C et al.: Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics Proteomics 6, 325-329 (2009).
17. Jeng YL, Wu MH, Huang HB et al.: The methylenetetrahydrofolate reductase 677C→T polymorphism and lung cancer risk in a Chinese population. Anticancer Res. 23, 5149-5152 (2003).
18. Mao R, Fan Y, Jin Y, Bai J, Fu S: Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. J. Hum. Genet. 53, 340-348 (2008).
19. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q: Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol. Biomarkers Prev. 10, 397-401 (2001). (Pubitemid 32703226)
20. Levine AJ, Figueiredo JC, Lee W et al.: A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 19, 1812-1821 (2010).
21. Lu M, Wang F, Qiu J: Methionine synthase A2756G polymorphism and breast cancer risk: a meta-analysis involving 18,953 subjects. Breast Cancer Res. Treat 123, 213-217 (2010).
22. Collin SM, Metcalfe C, Zuccolo L et al.: Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 18, 2528-2539 (2009)
23. Koppen IJ, Hermans FJ, Kaspers GJ: Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br. J. Haematol. 148, 3-14 (2009).
24. Liu H, Jin G, Wang H, Wu W et al.: Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer 61, 21-29 (2008).
25. Shi Q, Zhang Z, Li G et al.: Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenet. Genomics 15, 547-555 (2005). (Pubitemid 41044240)
26. Shi Q, Zhang Z, Neumann AS, Li G, Spitz MR, Wei Q: Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 26, 649-656 (2005). (Pubitemid 41214156)
27. Van de Vaart PJ, Belderbos J, De Jong D et al.: DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int. J. Cancer 89, 160-166 (2000). (Pubitemid 30185925)
28. Duffaudand F, Therasse P: New guidelines to evaluate the response to treatment in solid tumors. Bull. Cancer 87, 881-886 (2000). (Pubitemid 32094649)
29. Kim HN, Lee IK, Kim YK et al.: Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br. J. Haematol. 140, 287-294 (2008).
30. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5́-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197 (1995).
31. Zintzaras E: The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat. Appl. Genet. Mol. Biol. 9(1), Article21 (2010).
32. Hao L, Ma J, Zhu J et al.: High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J. Nutr. 137, 407-413 (2007). (Pubitemid 46213457)
33. Dhonukshe-Rutten RA, de Vries JH, de Bree A, van der Put N, van Staveren WA, de Groot LC: Dietary intake and status of folate and vitamin B12 and their association with homocysteine and cardiovascular disease in European populations. Eur. J. Clin. Nutr. 63, 18-30 (2009).
34. Cui LH, Shin MH, Kweon SS et al.: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population. BMC Cancer 10, 236 (2010).
35. Song C, Xing D, Tan W, Wei Q, Lin D: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 61, 3272-3275 (2001). (Pubitemid 32695011)
36. Wang LD, Guo RF, Fan ZM et al.: Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis. Esophagus 18, 177-184 (2005).
37. Liu L, Yang L, Zhang YC, Ai XF, Wang JX, Xiao ZJ: Polymorphisms of drug-metabolizing enzymes genes in a Han Chinese population. Zhonghua Yi Xue Za Zhi 89, 2675-2681 (2009).
38. Jones PA: Overview of cancer epigenetics. Semin. Hematol. 42, S3-S8 (2005). (Pubitemid 40961866)
39. Kim YI: Folate and carcinogenesis: evidence, mechanisms, and implications. J. Nutr. Biochem. 10, 66-88 (1999).
40. Yang GH, Ma JM, Liu N, Zhou LN: Smoking and passive smoking in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi 26(2) 77-83 (2005).
41. Wakelee HA, Chang ET, Gomez SL et al.: Lung cancer incidence in never smokers. J. Clin. Oncol. 25, 472-478 (2007). (Pubitemid 350002951)
42. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL: Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res. 66, 4961-4967 (2006).
43. Zhangand JJ, Smith KR: Household air pollution from coal and biomass fuels in China: measurements, health impacts, and interventions. Environ. Health Perspect. 115, 848-855 (2007). (Pubitemid 46902238)
44. Cheng YW, Hsieh LL, Lin PP et al.: Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ. Mol. Mutagen. 37, 304-310 (2001).
45. Wei Q, Cheng L, Amos CI et al.: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl Cancer Inst. 92, 1764-1772 (2000).
46. Lee MS, Su L, Mark EJ, Wain JC, Christiani DC: Genetic modifiers of carcinogen DNA adducts in target lung and peripheral blood mononuclear cells. Carcinogenesis 31, 2091-2096 (2010).
47. Alberola V, Sarries C, Rosell R et al.: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer 5, 360-365 (2004). (Pubitemid 39004333)
48. Smit EF, Burgers SA, Biesma B et al.: Randomized Phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 27, 2038-2045 (2009).
49. Ceppi P, Papotti M, Scagliotti G: New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. Adv. Med. Sci. 55, 22-25 (2010).
50. Kawakami K, Salonga D, Park JM et al.: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7, 4096-4101 (2001). (Pubitemid 34044633)
51. Takizawa M, Kawakami K, Obata T et al.: In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol. Rep. 15, 1533-1539 (2006).